<DOC>
	<DOCNO>NCT02226952</DOCNO>
	<brief_summary>Study assess antiviral efficacy , pharmacokinetics tolerability BILN 2061 ZW polyethyleneglycol 400 ( PEG 400 : ethanol ) drinking solution give two day bid patient chronic Hepatitis C Virus ( HCV ) infection .</brief_summary>
	<brief_title>Antiviral Efficacy , Pharmacokinetics Safety BILN 2061 ZW Patients With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Female male sex , age 18 year older Active , chronic Hepatitis C virus ( HCV ) infection Liver biopsy consistent active HCV infection obtain within last 12 month Written inform consent consistent International Committee Harmonization ( ICH ) / Good Clinical Practice ( GCP ) local legislation give prior study procedure HCV genotype I ( Group 1 , 2 , 4 5 ) nongenotype 1 ( Group 3 ) HCV load great 50,000 copy messenger ribonucleic acid ( mRNA ) per ml serum screen For Group 5 : Histology show moderate severe fibrosis ( portal fibrosis , septae , periportal portocentral septae ) , regenerative node incomplete complete cirrhosis , correspond Ishak score 3 4 , Metavir F2 F3 ( Ishak 5 ) Women childbearing potential breastfeeding woman . Postmenopausal woman less 6 month last menses , surgically sterilize hysterectomised patient le 3 month operation without negative serum pregnancy test Males use adequate form contraception ( condom , sterilisation least 6 month post operation ) partner childbearing potential ( criterion see ) use adequate form contraception ( hormonal contraceptive , oral injectable/ implantable , intrauterine device ( IUD ) ) Any additional plausible cause chronic liver disease , include presence virus know suspected cause hepatitis Ascites current evidence portal hypertension Histology show sign bridge high grade fibrosis ( e.g . Fibrosis &gt; = Grade 3 ( Ishak score ) &gt; = 2 ( Metavir score ) treatment group 1 , 2 , 3 , 4 Treatment group 5 : Histology show less moderate severe fibrosis ( portal fibrosis , septae , periportal portocentral septae ) , show regenerative node incomplete complete cirrhosis , correspond Ishak score 3 4 Metavir score F2 F3 ( F3 Ishak 5 ) History abuse alcohol within past twelve month Planned concurrent usage pharmacological therapy screening , include antiviral therapy Any concurrent infectious disease require antimicrobial treatment History malignancy ( except previously cure squamous cell basal cell carcinoma ) Usage investigational drug within thirty ( 30 ) day prior enrolment ; plan usage investigational drug course current study Known hypersensitivity drug Inability comply protocol Prior randomization trial ChildÂ´s B C liver disease screen ( treatment group 1 , 2 , 3 , 4 ) . Applicable treatment group 5 : For Bilirubin refer follow exclusion criterion Quick ( Prothrombin time ) &lt; 70 % Albumin &lt; 3.5 g/dl Clinical evidence ascites Clinical evidence encephalopathy Clinically apparent jaundice total bilirubin alkaline phosphatase ( AP ) exceed 1.5 x upper limit normal ( ULN ) screening ( treatment group 1 , 2 , 3 , 4 ) . Treatment group 5 ( BILN 2061 ZW , 200 mg bid/2 day patient advance liver fibrosis ) : Clinically apparent jaundice bilirubin &gt; = 2.0 mg/dl screening . Increased alkaline phosphatase ( AP ) allow . ALT AST &gt; 5 x ULN screen ( treatment group 1 , 2 , 3 , 4 ) . Treatment group 5 : ALT AST &gt; = 10 x ULN screen A platelet count le 100.000 platelet per mm3 screen White blood cell count le 2,000 cell per mm3 screen Positive test human immunodeficiency Virus ( HIV ) screen Positive test illicit unprescribed drug medication screen . Positive test cannabis may allow investigator ass result clinically significant Patients clinically significant laboratory abnormality base investigator 's medical assessment screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>